{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:08:46Z","timestamp":1794438526107,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-009125"],"award-info":[{"award-number":["INV-009125"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2016 the World Health Organization set the goal of eliminating hepatitis B globally by 2030. Horizontal transmission has been greatly reduced in most countries by scaling up coverage of the infant HBV vaccine series, and vertical transmission is therefore becoming increasingly dominant. Here we show that scaling up timely hepatitis B birth\u00a0dose vaccination to 90% of new-borns in 110 low- and middle-income countries by 2030 could prevent 710,000 (580,000 to 890,000) deaths in the 2020 to 2030 birth cohorts compared to status quo, with the greatest benefits in Africa. Maintaining this could lead to elimination by 2030 in the Americas, but not before 2059 in Africa. Drops in coverage due to disruptions in 2020 may lead to 15,000 additional deaths, mostly in South-East Asia and the Western Pacific. Delays in planned scale-up could lead to an additional 580,000 deaths globally in the 2020 to 2030 birth cohorts.<\/jats:p>","DOI":"10.1038\/s41467-021-26475-6","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T06:03:10Z","timestamp":1635400990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["The impact of the timely birth dose vaccine on the global elimination of hepatitis B"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-6703","authenticated-orcid":false,"given":"Margaret J.","family":"de Villiers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shevanthi","family":"Nayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9681-0424","authenticated-orcid":false,"given":"Timothy B.","family":"Hallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"26475_CR1","unstructured":"Global hepatitis report 2017 (World Health Organization, Geneva, 2017)."},{"key":"26475_CR2","unstructured":"Combating hepatitis B and C to reach elimination by 2030: advocacy brief (World Health Organization, Geneva, 2016)."},{"key":"26475_CR3","unstructured":"Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis (World Health Organization, Geneva, 2016)."},{"key":"26475_CR4","unstructured":"Hepatitis B vaccines: WHO position paper. in Weekly epidemiological record, Vol. 84 405\u2013420 (World Health Organization, 2009)."},{"key":"26475_CR5","doi-asserted-by":"crossref","unstructured":"Hepatitis B vaccines: WHO position paper--recommendations. Vaccine 28, 589\u2013590 (2010).","DOI":"10.1016\/j.vaccine.2009.10.110"},{"key":"26475_CR6","unstructured":"Hepatitis B vaccines: WHO position paper\u2014July 2017. in Weekly epidemiological record, Vol. 92 369\u2013392 (World Health Organization, 2017)."},{"key":"26475_CR7","doi-asserted-by":"crossref","unstructured":"Hepatitis B vaccines: WHO position paper, July 2017\u2014Recommendations. Vaccine 37, 223\u2013225 (2019).","DOI":"10.1016\/j.vaccine.2017.07.046"},{"key":"26475_CR8","doi-asserted-by":"crossref","unstructured":"Lee, C., Gong, Y., Brok, J., Boxall, E. H. & Gluud, C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev, CD004790-CD004790 (2006).","DOI":"10.1002\/14651858.CD004790.pub2"},{"key":"26475_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.gastro.2011.12.035","volume":"142","author":"HL Chen","year":"2012","unstructured":"Chen, H. L. et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 142, 773\u2013781 (2012).","journal-title":"Gastroenterology"},{"key":"26475_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/apt.13795","volume":"44","author":"E Keane","year":"2016","unstructured":"Keane, E., Funk, A. L. & Shimakawa, Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharm. Ther. 44, 1005\u20131017 (2016).","journal-title":"Aliment Pharm. Ther."},{"key":"26475_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.11604\/pamj.supp.2017.27.3.11544","volume":"27","author":"B Bodo","year":"2017","unstructured":"Bodo, B. & Malande, O. O. Delayed introduction of the birth dose of Hepatitis B vaccine in EPI programs in East Africa: a missed opportunity for combating vertical transmission of Hepatitis B. Pan Afr. Med. J. 27, 19\u201319 (2017).","journal-title":"Pan Afr. Med. J."},{"key":"26475_CR12","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1016\/j.vaccine.2017.04.020","volume":"35","author":"E Seremba","year":"2017","unstructured":"Seremba, E. et al. Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda. Vaccine 35, 2937\u20132942 (2017).","journal-title":"Vaccine"},{"key":"26475_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(20)30304-2","volume":"20","author":"R Nelson","year":"2020","unstructured":"Nelson, R. COVID-19 disrupts vaccine delivery. Lancet Infect. Dis. 20, 546 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"26475_CR14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S2468-1253(20)30238-7","volume":"5","author":"C Wingrove","year":"2020","unstructured":"Wingrove, C., Ferrier, L., James, C. & Wang, S. The impact of COVID-19 on hepatitis elimination. Lancet Gastroenterol. Hepatol. 5, 792\u2013794 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"26475_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S2468-1253(20)30305-8","volume":"5","author":"M Lemoine","year":"2020","unstructured":"Lemoine, M. et al. Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan Africa. Lancet Gastroenterol. Hepatol. 5, 966\u2013967 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"26475_CR16","doi-asserted-by":"publisher","first-page":"e004275","DOI":"10.1136\/bmjgh-2020-004275","volume":"6","author":"CM Pley","year":"2021","unstructured":"Pley, C. M., McNaughton, A. L., Matthews, P. C. & Louren\u00e7o, J. The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. BMJ Glob. health 6, e004275 (2021).","journal-title":"BMJ Glob. health"},{"key":"26475_CR17","unstructured":"Pulse survey on continuity of essential health services during the COVID-19 pandemic: interim report, 27 August 2020 (World Health Organization, Geneva, 2020)."},{"key":"26475_CR18","doi-asserted-by":"crossref","unstructured":"Saso, A., Skirrow, H. & Kampmann, B. Impact of COVID-19 on Immunization Services for Maternal and Infant Vaccines: Results of a Survey Conducted by Imprint-The Immunising Pregnant Women and Infants Network. Vaccines (Basel) 8 (2020).","DOI":"10.3390\/vaccines8030556"},{"key":"26475_CR19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/hep.28589","volume":"64","author":"WH Wen","year":"2016","unstructured":"Wen, W. H. et al. Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology 64, 1451\u20131461 (2016).","journal-title":"Hepatology"},{"key":"26475_CR20","unstructured":"Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy (World Health Organization, Geneva, 2020)."},{"key":"26475_CR21","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","volume":"374","author":"CQ Pan","year":"2016","unstructured":"Pan, C. Q. et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N. Engl. J. Med 374, 2324\u20132334 (2016).","journal-title":"N. Engl. J. Med"},{"key":"26475_CR22","doi-asserted-by":"crossref","unstructured":"Funk, A. L. et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis (2020).","DOI":"10.1016\/S1473-3099(20)30586-7"},{"key":"26475_CR23","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/apt.14068","volume":"45","author":"MH Hyun","year":"2017","unstructured":"Hyun, M. H. et al. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharm. Ther. 45, 1493\u20131505 (2017).","journal-title":"Aliment Pharm. Ther."},{"key":"26475_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/hep.28302","volume":"63","author":"RS Brown","year":"2016","unstructured":"Brown, R. S. et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology 63, 319\u2013333 (2016).","journal-title":"Hepatology"},{"key":"26475_CR25","doi-asserted-by":"crossref","unstructured":"Nayagam, S. et al. Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. Clinical Infectious Diseases (2020).","DOI":"10.1093\/cid\/ciaa134"},{"key":"26475_CR26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","volume":"16","author":"S Nayagam","year":"2016","unstructured":"Nayagam, S. et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect. Dis. 16, 1399\u20131408 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"26475_CR27","unstructured":"Gavi Alliance Update: UNICEF VIC 21 October 2020. (Gavi, The Vaccine Alliance, 2020)."},{"key":"26475_CR28","doi-asserted-by":"publisher","first-page":"e1264","DOI":"10.1016\/S2214-109X(20)30308-9","volume":"8","author":"K Abbas","year":"2020","unstructured":"Abbas, K. et al. Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit\u2013risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. Lancet Glob. Health 8, e1264\u2013e1272 (2020).","journal-title":"Lancet Glob. Health"},{"key":"26475_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.11604\/pamj.supp.2017.27.3.11981","volume":"27","author":"L Breakwell","year":"2017","unstructured":"Breakwell, L., Tevi-Benissan, C., Childs, L., Mihigo, R. & Tohme, R. The status of hepatitis B control in the African region. Pan Afr. Med J. 27, 17\u201317 (2017).","journal-title":"Pan Afr. Med J."},{"key":"26475_CR30","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/S2214-109X(18)30219-5","volume":"6","author":"N Scott","year":"2018","unstructured":"Scott, N. et al. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. Lancet Glob. Health 6, e659\u2013e667 (2018).","journal-title":"Lancet Glob. Health"},{"key":"26475_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/2230-8229.197176","volume":"24","author":"S Oberoi","year":"2017","unstructured":"Oberoi, S., Amarjit, S., Avneet, R., Neha, C. & Patnaik, S. Positive impact of rescheduling Bacillus Calmette-Gu\u00e9rin vaccination on vaccinations at birth. J. Fam. community Med. 24, 13\u201317 (2017).","journal-title":"J. Fam. community Med."},{"key":"26475_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"D Razavi-Shearer","year":"2018","unstructured":"Razavi-Shearer, D. et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3, 383\u2013403 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"26475_CR33","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/ije\/dyaa253","volume":"50","author":"N Schmit","year":"2021","unstructured":"Schmit, N., Nayagam, S., Thursz, M. R. & Hallett, T. B. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. Int. J. Epidemiol. 50, 560\u2013569 (2021).","journal-title":"Int. J. Epidemiol."},{"key":"26475_CR34","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/j.1440-1746.2005.03813.x","volume":"20","author":"X Lin","year":"2005","unstructured":"Lin, X. et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J. Gastroenterol. Hepatol. 20, 833\u2013843 (2005).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"26475_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich, G., Bortolotti, F. & Donato, F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48, 335\u2013352 (2008).","journal-title":"J. Hepatol."},{"issue":"Suppl 3","key":"26475_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3851\/IMP1621","volume":"15","author":"Y-F Liaw","year":"2010","unstructured":"Liaw, Y.-F., Brunetto, M. R. & Hadziyannis, S. The natural history of chronic HBV infection and geographical differences. Antivir. Ther. 15(Suppl 3), 25\u201333 (2010).","journal-title":"Antivir. Ther."},{"key":"26475_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12072-008-9112-z","volume":"3","author":"BJ McMahon","year":"2009","unstructured":"McMahon, B. J. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol. Int 3, 334\u2013342 (2009).","journal-title":"Hepatol. Int"},{"key":"26475_CR38","doi-asserted-by":"publisher","first-page":"e69430","DOI":"10.1371\/journal.pone.0069430","volume":"8","author":"Y Shimakawa","year":"2013","unstructured":"Shimakawa, Y., Yan, H. J., Tsuchiya, N., Bottomley, C. & Hall, A. J. Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: a systematic review. PLoS One 8, e69430 (2013).","journal-title":"PLoS One"},{"key":"26475_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/rmv.1885","volume":"26","author":"A Kramvis","year":"2016","unstructured":"Kramvis, A. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev. Med Virol. 26, 285\u2013303 (2016).","journal-title":"Rev. Med Virol."},{"key":"26475_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/jvh.13231","volume":"27","author":"S Nayagam","year":"2020","unstructured":"Nayagam, S., Shimakawa, Y. & Lemoine, M. Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world? J. Viral Hepat. 27, 342\u2013349 (2020).","journal-title":"J. Viral Hepat."},{"key":"26475_CR41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale, A. J. et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J. Hepatol. 73, 523\u2013532 (2020).","journal-title":"J. Hepatol."},{"key":"26475_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jpeds.2014.06.059","volume":"165","author":"YC Chiu","year":"2014","unstructured":"Chiu, Y. C. et al. Factors affecting the natural decay of hepatitis B surface antigen in children with chronic hepatitis B virus infection during long-term follow-up. J. Pediatr. 165, 767\u2013772.e761 (2014).","journal-title":"J. Pediatr."},{"key":"26475_CR43","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/liv.12814","volume":"35","author":"Y Shimakawa","year":"2015","unstructured":"Shimakawa, Y. et al. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. Liver Int 35, 2318\u20132326 (2015).","journal-title":"Liver Int"},{"key":"26475_CR44","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1136\/gutjnl-2015-309892","volume":"65","author":"Y Shimakawa","year":"2016","unstructured":"Shimakawa, Y. et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut 65, 2007\u20132016 (2016).","journal-title":"Gut"},{"key":"26475_CR45","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3201\/eid2305.161477","volume":"23","author":"F Cui","year":"2017","unstructured":"Cui, F. et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg. Infect. Dis. 23, 765\u2013772 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"26475_CR46","doi-asserted-by":"crossref","unstructured":"Ott, J. J., Stevens, G. A. & Wiersma, S. T. The risk of perinatal hepatitis B virus transmission: hepatitis B e-antigen (HBeAg) prevalence estimates for all world regions. BMC Infectious Diseases 12 (2012).","DOI":"10.1186\/1471-2334-12-131"},{"key":"26475_CR47","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott, J. J., Stevens, G. A., Groeger, J. & Wiersma, S. T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212\u20132219 (2012).","journal-title":"Vaccine"},{"key":"26475_CR48","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211\u20131259 (2017).","journal-title":"Lancet"},{"key":"26475_CR49","doi-asserted-by":"publisher","first-page":"e0237525","DOI":"10.1371\/journal.pone.0237525","volume":"15","author":"MJ de Villiers","year":"2020","unstructured":"de Villiers, M. J. et al. Modelling hepatitis B virus infection and impact of timely birth dose vaccine: a comparison of two simulation models. PLoS ONE 15, e0237525 (2020).","journal-title":"PLoS ONE"},{"key":"26475_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1098\/rsif.2008.0172","volume":"6","author":"T Toni","year":"2009","unstructured":"Toni, T., Welch, D., Strelkowa, N., Ipsen, A. & Stumpf, M. P. Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems. J. R. Soc. Interface 6, 187\u2013202 (2009).","journal-title":"J. R. Soc. Interface"},{"key":"26475_CR51","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1503\/cmaj.081112","volume":"180","author":"CO Mackie","year":"2009","unstructured":"Mackie, C. O., Buxton, J. A., Tadwalkar, S. & Patrick, D. M. Hepatitis B immunization strategies: timing is everything. Can. Med. Assoc. J. (CMAJ) 180, 196\u2013202 (2009).","journal-title":"Can. Med. Assoc. J. (CMAJ)"},{"key":"26475_CR52","doi-asserted-by":"crossref","unstructured":"Peto, T. J. et al. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986\u201390) and in the nationwide immunisation program. BMC Infectious Diseases 14 (2014).","DOI":"10.1186\/1471-2334-14-7"},{"key":"26475_CR53","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0140-6736(83)90624-4","volume":"2","author":"RP Beasley","year":"1983","unstructured":"Beasley, R. P. et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2, 1099\u20131102 (1983).","journal-title":"Lancet"},{"key":"26475_CR54","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/bmj.38719.435833.7C","volume":"332","author":"C Lee","year":"2006","unstructured":"Lee, C., Gong, Y., Brok, J., Boxall, E. H. & Gluud, C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332, 328\u2013336 (2006).","journal-title":"BMJ"},{"key":"26475_CR55","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1542\/peds.76.5.713","volume":"76","author":"ZY Xu","year":"1985","unstructured":"Xu, Z. Y. et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 76, 713\u2013718 (1985).","journal-title":"Pediatrics"},{"key":"26475_CR56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/oxfordjournals.aje.a112370","volume":"105","author":"RP Beasley","year":"1977","unstructured":"Beasley, R. P., Trepo, C., Stevens, C. E. & Szmuness, W. The e-antigen and vertical transmission of hepatitis B surface antigen. Am. J. Epidemiol. 105, 94\u201398 (1977).","journal-title":"Am. J. Epidemiol."},{"key":"26475_CR57","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0140-6736(84)92388-2","volume":"1","author":"VC Wong","year":"1984","unstructured":"Wong, V. C. et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1, 921\u2013926 (1984).","journal-title":"Lancet"},{"key":"26475_CR58","volume-title":"9.9.0.1467703 (R2020b)","author":"MATLAB.","year":"2020","unstructured":"MATLAB. 9.9.0.1467703 (R2020b). (The MathWorks Inc., Natick, Massachusetts, 2020)."},{"key":"26475_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H Wickham","year":"2016","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag, New York, 2016)."},{"key":"26475_CR60","unstructured":"South, A. rnaturalearth: World Map Data from Natural Earth. Vol. R package version 0.1.0 (2017)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26475-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T11:39:54Z","timestamp":1669981194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26475-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26475"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26475-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-370018\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"14 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: This work was carried out as part of the Vaccine Impact Modelling Consortium (\n                      \n                      ), but the views expressed are those of the authors and not necessarily those of the Consortium or its funders. The funders were given the opportunity to review this paper prior to publication, but the final decision on the content of the publication was taken by the authors. SN and TBH have received personal fees for technical consultation work with the World Health Organization on Hepatitis elimination, surveillance and monitoring, and for the preparation of reports for guidelines committees on the prevention of mother-to-child transmission. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6223"}}